<i>In vivo</i> phenotypic drug discovery: applying a behavioral assay to the discovery and optimization of novel antipsychotic agents
作者:Liming Shao、Una C. Campbell、Q. Kevin Fang、Noel A. Powell、John E. Campbell、Philip G. Jones、Taleen Hanania、Vadim Alexandrov、Irene Morganstern、Emily Sabath、Hua M. Zhong、Thomas H. Large、Kerry L. Spear
DOI:10.1039/c6md00128a
日期:——
A mouse-based assay (SmartCube) was used for both screening and lead optimization of a novel antipsychotic.
[EN] HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLES ET PROCÉDÉ D'UTILISATION CORRESPONDANT
申请人:SUNOVION PHARMACEUTICALS INC
公开号:WO2013119895A1
公开(公告)日:2013-08-15
Provided herein are thiophene compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or management of various neurological disorders, including but not limited to, psychosis and schizophrenia.
Object of the present invention are novel substituted compounds of the formula 1,
wherein A, R
1
, R
2
, R
3
and R
4
are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
Aryl and heteroaryl compounds, compositions, methods of use
申请人:Mjalli M.M. Adnan
公开号:US20050171148A1
公开(公告)日:2005-08-04
This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be useful as antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX and/or XI.